Mohammed Eslam
YOU?
Author Swipe
View article: OR21-05 A Multinational Study of Serum Metabolomics and Lipidomics in the Pathophysiology and Non-invasive Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease
OR21-05 A Multinational Study of Serum Metabolomics and Lipidomics in the Pathophysiology and Non-invasive Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease Open
Disclosure: K. Stefanakis: None. N. Perakakis: None. O. Verrastro: None. M. Garcovich: None. L. Riccardi: None. M. Eslam: None. G.E. Markakis: None. G. Papatheodoridis: None. G. Mingrone: None. J. George: None. C.S. Mantzoros: None. The gr…
View article: MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk Open
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over 30% of the global population. It is a multisystem condition with a strong association with cardiovascular disease (CVD), the leading cause of mortality worldwide. Ke…
View article: Drug pricing for hepatitis B and C in Australia and Japan
Drug pricing for hepatitis B and C in Australia and Japan Open
View article: Underrepresentation of Arabs in Functional Genetics Studies: Opportunities and Obstacles for Advancing Biology and Human Health
Underrepresentation of Arabs in Functional Genetics Studies: Opportunities and Obstacles for Advancing Biology and Human Health Open
A significant challenge to the transnational application of genetics and functional genomic studies is the underrepresentation of certain populations. In this work, we emphasise that while there are over 500 million Arabs living across 22 …
View article: Exploring the diagnostic accuracy of MAFLD, MASLD and metabolic syndrome in individuals with and without steatosis.
Exploring the diagnostic accuracy of MAFLD, MASLD and metabolic syndrome in individuals with and without steatosis. Open
Introduction and Objectives: The renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) marks a crucial mil…
View article: The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Open
View article: Alternative splicing: hallmark and therapeutic opportunity in metabolic liver disease
Alternative splicing: hallmark and therapeutic opportunity in metabolic liver disease Open
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the leading cause of chronic liver disease worldwide, with fibrosis recognized as the main prognostic factor and therapeutic target. While early-stage fibrosis is reve…
View article: Energy metabolism: An emerging therapeutic frontier in liver fibrosis
Energy metabolism: An emerging therapeutic frontier in liver fibrosis Open
Liver fibrosis is a progressive response to chronic liver diseases characterized by a wound-healing process that leads to the accumulation of fibrillary extracellular matrix (ECM) proteins in and around the liver tissue. If left untreated,…
View article: Metabolic dysfunction and kidney disease risk in individuals with MAFLD
Metabolic dysfunction and kidney disease risk in individuals with MAFLD Open
View article: From NAFPD to MAFPD: a literature review of implications of a nomenclature change
From NAFPD to MAFPD: a literature review of implications of a nomenclature change Open
Background and objective: obesity is a global health issue closely linked to multiple cardiovascular and metabolic conditions. The renaming of nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction associated fatty liver disease…
View article: Symmetric dimethylguanidino valeric acid, a novel single biomarker of hepatic steatosis
Symmetric dimethylguanidino valeric acid, a novel single biomarker of hepatic steatosis Open
View article: Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research Open
View article: Telehealth Use and Legal Considerations in Drug Health Services During Pandemics: Systematic Scoping Review
Telehealth Use and Legal Considerations in Drug Health Services During Pandemics: Systematic Scoping Review Open
Background The COVID-19 pandemic impacted patients with substance use disorder (SUD) more than the general population and resulted in substantially increased emergency department admissions. Routine care of patients attending drug health s…
View article: The <scp>MAFLD</scp> definition identifies three homogenous groups of patients
The <span>MAFLD</span> definition identifies three homogenous groups of patients Open
View article: MAFLD: from a disease framework to patient care
MAFLD: from a disease framework to patient care Open
View article: A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease Open
View article: MAFLD or MASLD: Let the evidence decide again
MAFLD or MASLD: Let the evidence decide again Open
View article: MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease Open
The MAFLD criteria better identify patients with CKD than do the MASLD criteria. Therefore, it is suggested that the MASLD criteria be reconsidered, as currently, the justification for changing from MAFLD to MASLD criteria may not be appro…
View article: A literature review of genetics and epigenetics of HCV-related hepatocellular carcinoma: translational impact
A literature review of genetics and epigenetics of HCV-related hepatocellular carcinoma: translational impact Open
By facilitating a more profound understanding of these aspects, this will ultimately foster the advancement of novel therapies and ultimately improve outcomes for patients.
View article: A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune Cells
A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune Cells Open
Background: Disease risk variants are likely to affect gene expression in a context- and cell-type specific manner. The membrane bound O-acyltransferase domain containing 7 (MBOAT7) rs8736 metabolic-dysfunction-associated fatty liver disea…
View article: Post-Liver Transplant Metabolic Syndrome
Post-Liver Transplant Metabolic Syndrome Open
View article: Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature
Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature Open
View article: Proteome profiling to advance management of metabolic dysfunction-associated fatty liver disease
Proteome profiling to advance management of metabolic dysfunction-associated fatty liver disease Open
View article: Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease Open
Objective Hyperferritinaemia is associated with liver fibrosis severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but the longitudinal implications have not been thoroughly investigated. We assessed…
View article: Implementation of a liver health check in people with type 2 diabetes
Implementation of a liver health check in people with type 2 diabetes Open
View article: Molecular Mechanisms Involved in MAFLD in Cholecystectomized Patients: A Cohort Study
Molecular Mechanisms Involved in MAFLD in Cholecystectomized Patients: A Cohort Study Open
Gallstone disease and metabolic dysfunction-associated fatty liver disease (MAFLD) share numerous common risk factors and progression determinants in that they both manifest as organ-specific consequences of metabolic dysfunction. Neverthe…
View article: Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease
Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease Open
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the important factors associated with chronic kidney disease (CKD), and there are many similarities between the two in adverse outcomes. N-terminal propepti…
View article: Two years on, a perspective on MAFLD
Two years on, a perspective on MAFLD Open
To provide clarity for research studies and clinical care, a set of positive criteria for adults and children with metabolic (dysfunction) associated fatty liver disease (MAFLD) was recently published and has subsequently been widely endor…
View article: The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study
The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study Open
View article: Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study
Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study Open